Phase II Study of TKI258 in Advanced Urothelial Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with transitional cell cancer of the bladder, urethra, ureter, or renal pelvis
Patients who have archival tumor tissue available for FGFR3 mutational status screening
Patients with progressive disease
Patients with measurable disease by RECIST
Patients previously treated with at least 1 but not more than 3 systemic cytotoxic regimens with at least one of these regimens including at least one of the following: cisplatin, carboplatin, gemcitabine or taxane administered in the perioperative or advanced setting
Age ≥ 18 years
WHO Performance Status ≤ 2
Patients willing and able to take oral medication, follow scheduled visits, treatment plan and laboratory tests
Patients with signed and witnessed informed consent form
Patients with adequate organ function
Patients with brain cancer
Patients with other cancers except for certain skin, cervical & prostate cancers
Patients who have not recovered from previous cancer treatment
Patients who have severe and/or uncontrolled medical conditions which could affect participation in the study
Other protocol-defined inclusion/exclusion criteria may apply